Sunesis Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
52-Week Range N/A
Volume1.20 million shs
Average Volume4.33 million shs
Market Capitalization$96.26 million
P/E RatioN/A
Dividend YieldN/A

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunesis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Sunesis Pharmaceuticals logo

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.18 out of 5 stars

Medical Sector

2037th out of 4,434 stocks

Pharmaceutical Preparations Industry

979th out of 1,734 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

Is Sunesis Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sunesis Pharmaceuticals stock.
View analyst ratings for Sunesis Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Sunesis Pharmaceuticals?

Wall Street analysts have given Sunesis Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sunesis Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.01.
View Sunesis Pharmaceuticals' earnings history

When did Sunesis Pharmaceuticals' stock split? How did Sunesis Pharmaceuticals' stock split work?

Shares of Sunesis Pharmaceuticals reverse split on the morning of Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 2nd 2020. An investor that had 100 shares of Sunesis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SNSS?

1 Wall Street analysts have issued 12 month price targets for Sunesis Pharmaceuticals' stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate Sunesis Pharmaceuticals' stock price to reach $12.00 in the next twelve months.
View analysts' price targets for Sunesis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the following people:
  • Dr. Judith A. Fox, Chief Scientific Officer and Exec. VP of R&D (Age 64, Pay $562.19k)
  • Mr. Parvinder S. Hyare, Interim CEO & Principal Exec. Officer (Age 50)
  • Ms. Tina Gullotta, Principal Financial Officer, VP of Fin. & Principal Accounting Officer (Age 46)
  • Dr. Deborah A. Thomas, Sr. VP, Regulatory Affairs, Quality Assurance & Pharmacovigilance
  • Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 58)

What is Dan Swisher Jr.'s approval rating as Sunesis Pharmaceuticals' CEO?

4 employees have rated Sunesis Pharmaceuticals CEO Dan Swisher Jr. on Dan Swisher Jr. has an approval rating of 82% among Sunesis Pharmaceuticals' employees.

Who are some of Sunesis Pharmaceuticals' key competitors?

What other stocks do shareholders of Sunesis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include (SLS), Amarin (AMRN), QUALCOMM (QCOM), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Exelixis (EXEL) and Novavax (NVAX).

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How much money does Sunesis Pharmaceuticals make?

Sunesis Pharmaceuticals has a market capitalization of $0.00 and generates $2.07 million in revenue each year. The biopharmaceutical company earns $-23,330,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis.

How many employees does Sunesis Pharmaceuticals have?

Sunesis Pharmaceuticals employs 24 workers across the globe.

What is Sunesis Pharmaceuticals' official website?

The official website for Sunesis Pharmaceuticals is

Where are Sunesis Pharmaceuticals' headquarters?

Sunesis Pharmaceuticals is headquartered at 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]

This page was last updated on 7/26/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.